Matches in Wikidata for { <http://www.wikidata.org/entity/Q66068533> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q66068533 description "clinical trial" @default.
- Q66068533 description "ensayu clínicu" @default.
- Q66068533 description "klinisch onderzoek" @default.
- Q66068533 description "клінічне випробування" @default.
- Q66068533 description "կլինիկական փորձարկում" @default.
- Q66068533 name "Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant" @default.
- Q66068533 name "Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant" @default.
- Q66068533 type Item @default.
- Q66068533 label "Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant" @default.
- Q66068533 label "Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant" @default.
- Q66068533 prefLabel "Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant" @default.
- Q66068533 prefLabel "Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant" @default.
- Q66068533 P1050 Q66068533-0F5075E4-9FBD-4801-B0E8-433437D309FB @default.
- Q66068533 P1132 Q66068533-21365259-7C61-4AA4-AAEA-CA49D7C1DAF1 @default.
- Q66068533 P1476 Q66068533-53EC93E3-330A-4581-9905-3AD25799CDB5 @default.
- Q66068533 P17 Q66068533-931A493E-0869-46EC-9302-5F305D1C4440 @default.
- Q66068533 P2899 Q66068533-0F87FD33-BE4C-498C-BDCF-9B1EDA4E0D50 @default.
- Q66068533 P3098 Q66068533-F901D548-07F7-444F-8A5C-5EDFB99AC95C @default.
- Q66068533 P31 Q66068533-14AB2C45-2D0E-4CAF-9F5F-8345055E42AE @default.
- Q66068533 P4135 Q66068533-3114CC99-4960-4C44-B2AE-CA520CC48A15 @default.
- Q66068533 P4844 Q66068533-206F97D1-138B-45E7-A5A9-11673D779A01 @default.
- Q66068533 P4844 Q66068533-6D8B09D9-17B3-48F4-9559-E516006DD81E @default.
- Q66068533 P4844 Q66068533-AAD7D569-5A2F-4D21-A476-5E652E315111 @default.
- Q66068533 P580 Q66068533-4F62CAFF-24E2-4024-B917-FFA41C353912 @default.
- Q66068533 P582 Q66068533-C180A47D-8A62-4AF6-BCAE-5BE901F07B11 @default.
- Q66068533 P6099 Q66068533-A94D73F1-688E-4746-919A-49ADA7F70ACE @default.
- Q66068533 P6099 Q66068533-BD92FE38-862F-40A1-ACF6-4D93D339348E @default.
- Q66068533 P8363 Q66068533-E589BEC0-97F0-4099-9419-6A9D9BFD4A01 @default.
- Q66068533 P1050 Q29496 @default.
- Q66068533 P1132 "+74" @default.
- Q66068533 P1476 "Phase I/II Study of Sorafenib Added to Busulfan and Fludarabine Conditioning Regimen in Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation" @default.
- Q66068533 P17 Q30 @default.
- Q66068533 P2899 "+18" @default.
- Q66068533 P3098 "NCT03247088" @default.
- Q66068533 P31 Q30612 @default.
- Q66068533 P4135 "+70" @default.
- Q66068533 P4844 Q185916 @default.
- Q66068533 P4844 Q3950557 @default.
- Q66068533 P4844 Q408524 @default.
- Q66068533 P580 "2017-07-30T00:00:00Z" @default.
- Q66068533 P582 "2021-07-30T00:00:00Z" @default.
- Q66068533 P6099 Q42824440 @default.
- Q66068533 P6099 Q5452194 @default.
- Q66068533 P8363 Q78089383 @default.